retatrutide glp-1 gip glucagon receptor agonist Science Behind GLP 1 and Agonists for Obesity Research | News & Announcements Glucagon-like peptide-1 receptor agonists in
Description
Researchers who study the pancreatic peptide hormone system will recognize glucagon as the metabolic counterweight to insulin, and harnessing it pharmacologically opens therapeutic possibilities that the research community has pursued for decades
Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W
3 Biotech (2021) 11(4):179
In one study, 42.23% of those on GLP-1 drugs reported nausea and 21.90% reported vomiting
But not without adverse events
S.) 171192 (Springer International Publishing, 2021)
